Evidence map›Paper›PMID 29212473›Full record

ArticleBMC ophthalmology2017

Case report: bilateral Mooren ulcer in association with hepatitis C.

Vesa Aaltonen, Mari Alavesa, Laura Pirilä, Eija Vesti, Mohammad Al-Juhaish

Open access · goldAbstract readCase Reports
In one paragraph

Article in BMC ophthalmology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Vesa AaltonenDepartment of Ophthalmology, Turku University Hospital, PO Box 52, FIN-20521, Turku, Finland. vesa.aaltonen@tyks.fi.ORCID http://orcid.org/0000-0002-0136-9999
Mari AlavesaDepartment of Ophthalmology, Turku University Hospital, PO Box 52, FIN-20521, Turku, Finland.
Laura PiriläDepartment of Rheumatology, Division of Medicine, Turku University Hospital, Box 52, FIN-20521, Turku, PO, Finland.
Eija VestiDepartment of Ophthalmology, Turku University Hospital, PO Box 52, FIN-20521, Turku, Finland.
Mohammad Al-JuhaishDepartment of Ophthalmology, Turku University Hospital, PO Box 52, FIN-20521, Turku, Finland.
University of Turku · FITurku University Hospital · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMooren ulcer has been considered as an idiopathic autoimmune keratitis. However, it has been in some cases suggested to be associated with hepatitis C, although the evidence is very vague. CASE PRESENTATION: We present a case of a man who was diagnosed with a primary Mooren ulcer in his right eye. The eye became blind despite of intensive treatment with local medications and extensive surgical procedures. After 10 years, the patient was diagnosed with the same disease, now in his left, previously healthy eye. There was no history that would suggest a secondary Mooren ulcer, but a chronic hepatitis C infection was detected. Treatment was targeted against hepatitis C (ribavirin and interferon) in addition to immunosuppressive medical and surgical treatment which resulted in a full and more than 6 years lasting remission of the disease.

conclusionsWhether the immunomodulatory and immunosuppressive medication against hepatitis C was the key reason for the good results in the treatment of the second eye, remains elusive. The causality of hepatitis C with respect to the pathogenesis of Mooren ulcer on this patient remains open, but should be considered as one of the possible etiological factors of the disease.

Indexed as

AgedAntiviral AgentsConjunctival DiseasesCorneal UlcerEye Infections, ViralHepatitis CHumansInterferon-alphaInterferon alpha-2MalePolyethylene GlycolsRecombinant ProteinsRibavirinAntiviral AgentsInterferon-alphaInterferon alpha-2peginterferon alfa-2bPolyethylene GlycolsRecombinant ProteinsRibavirinHepatitis CImmunomodulationImmunosuppressionKeratitisMooren ulcer

Identifiers

PMID29212473
PMCPMC5719567
OpenAlexW2771774805

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.